Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According to the American Heart Association (“AHA”), cardiovascular disease accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the nation’s number one killer. Into that persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. What makes Cardio Diagnostics’ approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company’s recent commercial and regulatory milestones give additional shape to the investment thesis.
The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the condition. By leveraging advanced technologies, Cardio Diagnostics aims to shift the paradigm from reactive treatment to proactive early detection, potentially saving lives and reducing healthcare expenditures.
For more information on Cardio Diagnostics, visit the company’s newsroom at https://ibn.fm/CDIO. InvestorWire, a specialized communications platform, syndicates press releases for private and public companies. It is part of the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to serve companies wanting to reach investors, influencers, consumers, journalists, and the public. For more information, visit https://www.InvestorWire.com and see full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.
InvestorWire is powered by IBN, based in Austin, Texas. The company can be contacted at 512.354.7000 or via email at Editor@InvestorWire.com. The latest news and updates relating to CDIO are available in the company’s newsroom.
